Silva, Marcos Vinícius Ferreira
(Faculdade de Farmá)
,
Loures, Cristina de Mello Gomide
(cia, Universidade Federal de Minas Gerais, Avenida Presidente Antô)
,
Alves, Luan Carlos Vieira
(nio Carlos, 6627 –)
,
de Souza, Leonardo Cruz
(Pampulha, Belo Horizonte, Minas Gerais 31270-901 Brazil)
,
Borges, Karina Braga Gomes
(Faculdade de Farmá)
,
Carvalho, Maria das Graças
(cia, Universidade Federal de Minas Gerais, Avenida Presidente Antô)
Alzheimer’s disease (AD) is the most common type of dementia and typically manifests through a progressive loss of episodic memory and cognitive function, subsequently causing language and visuospatial skills deficiencies, which are often accompanied by behavioral disorders such as apathy, aggressiv...
Alzheimer’s disease (AD) is the most common type of dementia and typically manifests through a progressive loss of episodic memory and cognitive function, subsequently causing language and visuospatial skills deficiencies, which are often accompanied by behavioral disorders such as apathy, aggressiveness and depression. The presence of extracellular plaques of insoluble β-amyloid peptide (Aβ) and neurofibrillary tangles (NFT) containing hyperphosphorylated tau protein (P-tau) in the neuronal cytoplasm is a remarkable pathophysiological cause in patients’ brains. Approximately 70% of the risk of developing AD can be attributed to genetics. However, acquired factors such as cerebrovascular diseases, diabetes, hypertension, obesity and dyslipidemia increase the risk of AD development. The aim of the present minireview was to summarize the pathophysiological mechanism and the main risk factors for AD. As a complement, some protective factors associated with a lower risk of disease incidence, such as cognitive reserve, physical activity and diet will also be addressed.
Alzheimer’s disease (AD) is the most common type of dementia and typically manifests through a progressive loss of episodic memory and cognitive function, subsequently causing language and visuospatial skills deficiencies, which are often accompanied by behavioral disorders such as apathy, aggressiveness and depression. The presence of extracellular plaques of insoluble β-amyloid peptide (Aβ) and neurofibrillary tangles (NFT) containing hyperphosphorylated tau protein (P-tau) in the neuronal cytoplasm is a remarkable pathophysiological cause in patients’ brains. Approximately 70% of the risk of developing AD can be attributed to genetics. However, acquired factors such as cerebrovascular diseases, diabetes, hypertension, obesity and dyslipidemia increase the risk of AD development. The aim of the present minireview was to summarize the pathophysiological mechanism and the main risk factors for AD. As a complement, some protective factors associated with a lower risk of disease incidence, such as cognitive reserve, physical activity and diet will also be addressed.
1. Ballard C Gauthier S Corbett A Brayne C Aarsland D Jones E Alzheimer's disease Lancet. 2011 377 9770 1019 1031 10.1016/S0140-6736(10)61349-9 21371747
2. Ferreira D Perestelo-Perez L Westman E Wahlund LO Sarria A Serrano-Aguilar P Meta-review of CSF Core biomarkers in Alzheimer's disease: the state-of-the-art after the new revised diagnostic criteria Front Aging Neurosci 2014 6 47 24715863
3. IDd A FHdEdM G Forlenza OV UdS P HLd B Alzheimer disease: correlation between memory and autonomy Rev psiquiatr clín 2005 32 3 131 136 10.1590/S0101-60832005000300005
4. Shinohara M Sato N Shimamura M Kurinami H Hamasaki T Chatterjee A Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors Front Aging Neurosci 2014 6 71 10.3389/fnagi.2014.00071 24795626
5. Cortes-Canteli M Paul J Norris EH Bronstein R Ahn HJ Zamolodchikov D Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease Neuron. 2010 66 5 695 709 10.1016/j.neuron.2010.05.014 20547128
6. Bateman RJ Xiong C Benzinger TLS Fagan AM Goate A Fox NC Marcus DS Cairns NJ Xie X Blazey TM Holtzman DM Santacruz A Buckles V Oliver A Moulder K Aisen PS Ghetti B Klunk WE McDade E Martins RN Masters CL Mayeux R Ringman JM Rossor MN Schofield PR Sperling RA Salloway S Morris JC Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease N Engl J Med 2012 367 795 804 10.1056/NEJMoa1202753 22784036
7. Murray ME Graff-Radford NR Ross OA Petersen RC Duara R Dickson DW Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study Lancet Neurol 2011 10 9 785 796 10.1016/S1474-4422(11)70156-9 21802369
8. de Souza LC Sarazin M Teixeira-Junior AL Caramelli P Santos AE Dubois B Biological markers of Alzheimer's disease Arq Neuropsiquiatr 2014 72 3 227 231 10.1590/0004-282X20130233 24676441
9. Kling MA Trojanowski JQ Wolk DA Lee VM Arnold SE Vascular disease and dementias: paradigm shifts to drive research in new directions Alzheimers Dement 2013 9 1 76 92 10.1016/j.jalz.2012.02.007 23183137
10. Kang S Lee YH Lee JE Metabolism-centric overview of the pathogenesis of Alzheimer's disease Yonsei Med J 2017 58 3 479 488 10.3349/ymj.2017.58.3.479 28332351
12. Hardy J Selkoe DJ The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science. 2002 297 5580 353 356 10.1126/science.1072994 12130773
14. Muller UC Deller T Korte M Not just amyloid: physiological functions of the amyloid precursor protein family Nat Rev Neurosci 2017 18 5 281 298 10.1038/nrn.2017.29 28360418
15. Doran E Keator D Head E Phelan MJ Kim R Totoiu M Down syndrome, partial trisomy 21, and absence of Alzheimer's disease: the role of APP J Alzheimers Dis 2017 56 2 459 470 10.3233/JAD-160836 27983553
18. Zhang H Ma Q Zhang YW Xu H Proteolytic processing of Alzheimer's beta-amyloid precursor protein J Neurochem 2012 120 Suppl 1 9 21 10.1111/j.1471-4159.2011.07519.x 22122372
19. Martorana A Di Lorenzo F Belli L Sancesario G Toniolo S Sallustio F Cerebrospinal fluid Abeta42 levels: when physiological become pathological state CNS Neurosci Ther 2015 21 12 921 925 10.1111/cns.12476 26555572
20. Naslund J Haroutunian V Mohs R Davis KL Davies P Greengard P Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline Jama. 2000 283 12 1571 1577 10.1001/jama.283.12.1571 10735393
21. Grimmer T Riemenschneider M Forstl H Henriksen G Klunk WE Mathis CA Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid Biol Psychiatry 2009 65 11 927 934 10.1016/j.biopsych.2009.01.027 19268916
22. Tapiola T Alafuzoff I Herukka SK Parkkinen L Hartikainen P Soininen H Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 2009 66 3 382 389 10.1001/archneurol.2008.596 19273758
24. Lee SJ Nam E Lee HJ Savelieff MG Lim MH Towards an understanding of amyloid-beta oligomers: characterization, toxicity mechanisms, and inhibitors Chem Soc Rev 2017 46 2 310 323 10.1039/C6CS00731G 27878186
25. Blurton-Jones M Laferla FM Pathways by which Abeta facilitates tau pathology Curr Alzheimer Res 2006 3 5 437 448 10.2174/156720506779025242 17168643
28. Nelson PT Alafuzoff I Bigio EH Bouras C Braak H Cairns NJ Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature J Neuropathol Exp Neurol 2012 71 5 362 381 10.1097/NEN.0b013e31825018f7 22487856
30. Giri M Zhang M Lu Y Genes associated with Alzheimer's disease: an overview and current status Clin Interv Aging 2016 11 665 681 10.2147/CIA.S105769 27274215
31. Cacace R Sleegers K Van Broeckhoven C Molecular genetics of early-onset Alzheimer's disease revisited Alzheimers Dement 2016 12 6 733 748 10.1016/j.jalz.2016.01.012 27016693
32. Calero M Gómez-Ramos A Calero O Soriano E Avila J Medina M Additional mechanisms conferring genetic susceptibility to Alzheimer’s disease Front Cell Neurosci. 2015 9 138 10.3389/fncel.2015.00138 25914626
34. Campion D Dumanchin C Hannequin D Dubois B Belliard S Puel M Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum Am J Hum Genet 1999 65 664 670 10.1086/302553 10441572
35. Corbo RM Scacchi R Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a ‘thrifty’ allele? Ann Hum Genet 1999 63 Pt 4 301 310 10.1046/j.1469-1809.1999.6340301.x 10738542
39. Hauser PS Narayanaswami V Ryan RO Apolipoprotein E: from lipid transport to neurobiology Prog Lipid Res 2011 50 1 62 74 10.1016/j.plipres.2010.09.001 20854843
40. Jonsson T Stefansson H Steinberg S Jonsdottir I Jonsson PV Snaedal J Variant of TREM2 associated with the risk of Alzheimer's disease N Engl J Med 2013 368 2 107 116 10.1056/NEJMoa1211103 23150908
41. Guerreiro R Wojtas A Bras J Carrasquillo M Rogaeva E Majounie E TREM2 variants in Alzheimer's disease N Engl J Med 2013 368 2 117 127 10.1056/NEJMoa1211851 23150934
42. Allcock RJ Barrow AD Forbes S Beck S Trowsdale J The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44 Eur J Immunol 2003 33 2 567 577 10.1002/immu.200310033 12645956
43. Jiang T Zhang YD Gao Q Ou Z Gong PY Shi JQ TREM2 ameliorates neuronal tau pathology through suppression of microglial inflammatory response Inflammation 2018 41 3 811 23 10.1007/s10753-018-0735-5 29362997
44. Mecca C Giambanco I Donato R Arcuri C Microglia and Aging: The Role of the TREM2-DAP12 and CX3CL1-CX3CR1 Axes Int J Mol Sci 2018 19 1 318 10.3390/ijms19010318
45. Xiang X Werner G Bohrmann B Liesz A Mazaheri F Capell A TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance EMBO Mol Med 2016 8 992 1004 10.15252/emmm.201606370 27402340
49. Liu W Wong A Law AC Mok VC Cerebrovascular disease, amyloid plaques, and dementia Stroke. 2015 46 5 1402 1407 10.1161/STROKEAHA.114.006571 25765727
51. Skoog I Lernfelt B Landahl S Palmertz B Andreasson LA Nilsson L 15-year longitudinal study of blood pressure and dementia Lancet. 1996 347 9009 1141 1145 10.1016/S0140-6736(96)90608-X 8609748
52. Staessen JA Richart T Birkenhager WH Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain Hypertension. 2007 49 3 389 400 10.1161/01.HYP.0000258151.00728.d8 17283254
54. Li X Song D Leng SX Link between type 2 diabetes and Alzheimer’s disease: from epidemiology to mechanism and treatment Clin Interv Aging 2015 10 549 560 10.2147/CIA.S74042 25792818
56. Ko Shun-Yao Ko Hshin-An Chu Kuo-Hsiung Shieh Tzong-Ming Chi Tzong-Cherng Chen Hong-I Chang Weng-Cheng Chang Shu-Shing The Possible Mechanism of Advanced Glycation End Products (AGEs) for Alzheimer’s Disease PLOS ONE 2015 10 11 e0143345 10.1371/journal.pone.0143345 26587989
57. Li XH Du LL Cheng XS Jiang X Zhang Y Lv BL Glycation exacerbates the neuronal toxicity of beta-amyloid Cell Death Dis 2013 4 e673 10.1038/cddis.2013.180 23764854
58. Profenno LA Porsteinsson AP Faraone SV Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders Biol Psychiatry 2010 67 6 505 512 10.1016/j.biopsych.2009.02.013 19358976
59. Fitzpatrick AL Kuller LH Lopez OL Diehr P O'Meara ES Longstreth WT Jr Midlife and late-life obesity and the risk of dementia: cardiovascular health study Arch Neurol 2009 66 3 336 342 10.1001/archneurol.2008.582 19273752
60. Anstey KJ Cherbuin N Budge M Young J Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies Obes Rev 2011 12 5 e426 e437 10.1111/j.1467-789X.2010.00825.x 21348917
61. Popp J Meichsner S Kolsch H Lewczuk P Maier W Kornhuber J Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease Biochem Pharmacol 2013 86 1 37 42 10.1016/j.bcp.2012.12.007 23291240
62. Xue-shan Z Juan P Qi W Zhong R Li-hong P Zhi-han T Imbalanced cholesterol metabolism in Alzheimer's disease Clin Chim Acta 2016 456 107 114 10.1016/j.cca.2016.02.024 26944571
63. Ricciarelli R Canepa E Marengo B Marinari UM Poli G Pronzato MA Cholesterol and Alzheimer's disease: a still poorly understood correlation IUBMB Life 2012 64 12 931 935 10.1002/iub.1091 23124820
64. Ullrich C Pirchl M Humpel C Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits Mol Cell Neurosci 2010 45 408 417 10.1016/j.mcn.2010.08.001 20696249
65. Hendrie HC Hake A Lane K Purnell C Unverzagt F Smith-Gamble V Statin use, incident dementia and Alzheimer disease in elderly African Americans Ethn Dis 2015 25 3 345 354 10.18865/ed.25.3.345 26673814
66. Haag MD Hofman A Koudstaal PJ Stricker BH Breteler MM Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study J Neurol Neurosurg Psychiatry 2009 80 1 13 17 10.1136/jnnp.2008.150433 18931004
67. Lin FC Chuang YS Hsieh HM Lee TC Chiu KF Liu CK Early statin use and the progression of Alzheimer disease: a Total population-based case-control study Medicine (Baltimore) 2015 94 47 e2143 10.1097/MD.0000000000002143 26632742
68. Simons M Schwarzler F Lutjohann D von Bergmann K Beyreuther K Dichgans J Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial Ann Neurol 2002 52 3 346 350 10.1002/ana.10292 12205648
69. Sano M Bell KL Galasko D Galvin JE Thomas RG van Dyck CH A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology. 2011 77 6 556 563 10.1212/WNL.0b013e318228bf11 21795660
72. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 360 9326 7 22 10.1016/S0140-6736(02)09327-3 12114036
73. Song Y Nie H Xu Y Zhang L Wu Y Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies Geriatr Gerontol Int 2013 13 4 817 824 10.1111/ggi.12044 23461525
74. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;(1):Cd003160. 10.1002/14651858.CD003160.pub3.
75. Hakansson K. Rovio S. Helkala E.-L. Vilska A.-R. Winblad B. Soininen H. Nissinen A. Mohammed A. H Kivipelto M. Association between mid-life marital status and cognitive function in later life: population based cohort study BMJ 2009 339 jul02 2 b2462 b2462 10.1136/bmj.b2462 19574312
76. Fan LY Sun Y Lee HJ Yang SC Chen TF Lin KN Marital status, lifestyle and dementia: a Nationwide survey in Taiwan PLoS One 2015 10 9 e0139154 10.1371/journal.pone.0139154 26413719
77. Sommerlad A Ruegger J Singh-Manoux A Lewis G Livingston G Marriage and risk of dementia: systematic review and meta-analysis of observational studies J Neurol Neurosurg Psychiatry 2018 89 3 231 238 10.1136/jnnp-2017-316274 29183957
78. Ray B Gaskins DL Sajdyk TJ Spence JP Fitz SD Shekhar A Restraint stress and repeated corticotrophin-releasing factor receptor activation in the amygdala both increase amyloid-beta precursor protein and amyloid-beta peptide but have divergent effects on brain-derived neurotrophic factor and pre-synaptic proteins in the prefrontal cortex of rats Neuroscience. 2011 184 139 150 10.1016/j.neuroscience.2011.03.067 21477639
79. Lesuis SL Maurin H Borghgraef P Lucassen PJ Van Leuven F Krugers HJ Positive and negative early life experiences differentially modulate long term survival and amyloid protein levels in a mouse model of Alzheimer's disease Oncotarget. 2016 7 26 39118 39135 10.18632/oncotarget.9776 27259247
81. Carroll JC Iba M Bangasser DA Valentino RJ James MJ Brunden KR Chronic stress exacerbates tau pathology, neurodegeneration, and cognitive performance through a corticotropin-releasing factor receptor-dependent mechanism in a transgenic mouse model of tauopathy J Neurosci 2011 31 40 14436 14449 10.1523/JNEUROSCI.3836-11.2011 21976528
83. Zverova M Fisar Z Jirak R Kitzlerova E Hroudova J Raboch J Plasma cortisol in Alzheimer's disease with or without depressive symptoms Med Sci Monit 2013 19 681 689 10.12659/MSM.889110 23955525
84. Wang LY Raskind MA Wilkinson CW Shofer JB Sikkema C Szot P Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia Int J Geriatr Psychiatry 2018 33 5 763 768 10.1002/gps.4856 29446123
88. Schrijvers EM Direk N Koudstaal PJ Kirschbaum C Hofman A Tiemeier H Associations of serum cortisol with cognitive function and dementia: the Rotterdam study J Alzheimers Dis 2011 25 4 671 677 10.3233/JAD-2011-110224 21483093
90. Ricci S Fuso A Ippoliti F Businaro R Stress-induced cytokines and neuronal dysfunction in Alzheimer's disease J Alzheimers Dis 2012 28 1 11 24 10.3233/JAD-2011-110821 22124029
91. Vilalta-Franch J Lopez-Pousa S Llinas-Regla J Calvo-Perxas L Merino-Aguado J Garre-Olmo J Depression subtypes and 5-year risk of dementia and Alzheimer disease in patients aged 70 years Int J Geriatr Psychiatry 2013 28 4 341 350 10.1002/gps.3826 22588687
92. Wu Kuan-Yi Lin Kun-Ju Chen Chia-Hsiang Chen Cheng-Sheng Liu Chia-Yih Huang Sheng-Yao Yen Tzu-Chen Hsiao Ing-Tsung Diversity of neurodegenerative pathophysiology in nondemented patients with major depressive disorder: Evidence of cerebral amyloidosis and hippocampal atrophy Brain and Behavior 2018 8 7 e01016 10.1002/brb3.1016 29927088
93. Proserpio P Arnaldi D Nobili F Nobili L Integrating sleep and Alzheimer's disease pathophysiology: hints for sleep disorders management J Alzheimers Dis 2018 63 3 871 886 10.3233/JAD-180041 29710720
94. Shi L Chen SJ Ma MY Bao YP Han Y Wang YM Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis Sleep Med Rev 2018 40 4 16 10.1016/j.smrv.2017.06.010 28890168
95. Traber MG van der Vliet A Reznick AZ Cross CE Tobacco-related diseases. Is there a role for antioxidant micronutrient supplementation? Clin Chest Med 2000 21 1 173 187 10.1016/S0272-5231(05)70016-2 10763098
97. Cataldo JK Prochaska JJ Glantz SA Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation J Alzheimers Dis 2010 19 2 465 480 10.3233/JAD-2010-1240 20110594
100. Stern Y Gurland B Tatemichi TK Tang MX Wilder D Mayeux R Influence of education and occupation on the incidence of Alzheimer's disease Jama. 1994 271 13 1004 1010 10.1001/jama.1994.03510370056032 8139057
101. Scarmeas N Levy G Tang MX Manly J Stern Y Influence of leisure activity on the incidence of Alzheimer’s disease Neurology. 2001 57 12 2236 2242 10.1212/WNL.57.12.2236 11756603
102. Hamer M Chida Y Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence Psychol Med 2009 39 1 3 11 10.1017/S0033291708003681 18570697
103. Mendiola-Precoma J Berumen LC Padilla K Garcia-Alcocer G Therapies for prevention and treatment of Alzheimer's disease Biomed Res Int 2016 2016 2589276 10.1155/2016/2589276 27547756
104. Paillard T Rolland Y de Souto Barreto P Protective effects of physical exercise in Alzheimer's disease and Parkinson's disease: a narrative review J Clin Neurol 2015 11 3 212 219 10.3988/jcn.2015.11.3.212 26174783
105. Huang EJ Reichardt LF Neurotrophins: roles in neuronal development and function* Annu Rev Neurosci 2001 24 677 736 10.1146/annurev.neuro.24.1.677 11520916
106. de Wilde MC Vellas B Girault E Yavuz AC Sijben JW Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses Alzheimers Dement (N Y) 2017 3 416 431 29067348
107. Scarmeas N Stern Y Mayeux R Manly JJ Schupf N Luchsinger JA Mediterranean diet and mild cognitive impairment Arch Neurol 2009 66 2 216 225 10.1001/archneurol.2008.536 19204158
108. Smith PJ Blumenthal JA Diet and Neurocognition: review of evidence and methodological considerations Curr Aging Sci 2010 3 1 57 66 10.2174/1874609811003010057 20298171
109. van Wijk N Broersen LM de Wilde MC Hageman RJ Groenendijk M Sijben JW Targeting synaptic dysfunction in Alzheimer's disease by administering a specific nutrient combination J Alzheimers Dis 2014 38 3 459 479 10.3233/JAD-130998 23985420
112. Knekt P Saaksjarvi K Jarvinen R Marniemi J Mannisto S Kanerva N Serum 25-hydroxyvitamin d concentration and risk of dementia Epidemiology. 2014 25 6 799 804 10.1097/EDE.0000000000000175 25215530
113. Shen L Ji HF Vitamin D deficiency is associated with increased risk of Alzheimer's disease and dementia: evidence from meta-analysis Nutr J 2015 14 76 10.1186/s12937-015-0063-7 26231781
114. Licher S de Bruijn R Wolters FJ Zillikens MC Ikram MA Ikram MK Vitamin D and the risk of dementia: the Rotterdam study J Alzheimers Dis 2017 60 3 989 997 10.3233/JAD-170407 28984598
115. Landel V, Annweiler C, Millet P, Morello M, Féron F. Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails. J Alzheimers Dis. 2016;53:419–44.
116. Grimm Marcus Thiel Andrea Lauer Anna Winkler Jakob Lehmann Johannes Regner Liesa Nelke Christopher Janitschke Daniel Benoist Céline Streidenberger Olga Stötzel Hannah Endres Kristina Herr Christian Beisswenger Christoph Grimm Heike Bals Robert Lammert Frank Hartmann Tobias Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation International Journal of Molecular Sciences 2017 18 12 2764 10.3390/ijms18122764
117. Briones TL Darwish H Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden J Neuroinflammation 2012 9 244 10.1186/1742-2094-9-244 23098125
118. Mizwicki MT Menegaz D Zhang J Barrientos-Duran A Tse S Cashman JR Genomic and nongenomic signaling induced by 1alpha,25(OH)2-vitamin D3 promotes the recovery of amyloid-beta phagocytosis by Alzheimer's disease macrophages J Alzheimers Dis 2012 29 1 51 62 10.3233/JAD-2012-110560 22207005
119. Masoumi A Goldenson B Ghirmai S Avagyan H Zaghi J Abel K 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients J Alzheimers Dis 2009 17 3 703 717 10.3233/JAD-2009-1080 19433889
120. Gezen-Ak D Dursun E Bilgic B Hanagasi H Ertan T Gurvit H Vitamin D receptor gene haplotype is associated with late-onset Alzheimer's disease Tohoku J Exp Med 2012 228 3 189 196 10.1620/tjem.228.189 23076256
121. Annweiler C Herrmann FR Fantino B Brugg B Beauchet O Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study Cogn Behav Neurol 2012 25 3 121 127 10.1097/WNN.0b013e31826df647 22960436
122. Annweiler C Rolland Y Schott AM Blain H Vellas B Herrmann FR Higher vitamin D dietary intake is associated with lower risk of alzheimer's disease: a 7-year follow-up J Gerontol A Biol Sci Med Sci 2012 67 11 1205 11 10.1093/gerona/gls107 22503994
123. Stein MS Scherer SC Ladd KS Harrison LC A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease J Alzheimers Dis 2011 26 3 477 484 10.3233/JAD-2011-110149 21694461
124. Miller BJ Whisner CM Johnston CS Vitamin D supplementation appears to increase plasma Abeta40 in vitamin D insufficient older adults: a pilot randomized controlled trial J Alzheimers Dis 2016 52 3 843 847 10.3233/JAD-150901 27031473
125. Li R Cui J Shen Y Brain sex matters: estrogen in cognition and Alzheimer’s disease Mol Cell Endocrinol 2014 389 0 13 21 10.1016/j.mce.2013.12.018 24418360
126. Zárate S, Stevnsner T, Gredilla R. Role of Estrogen and Other Sex Hormones in Brain Aging. Neuroprotection and DNA Repair. Front Aging Neurosci. 2017;9:430.
127. Depypere H Vierin A Weyers S Sieben A Alzheimer's disease, apolipoprotein E and hormone replacement therapy Maturitas. 2016 94 98 105 10.1016/j.maturitas.2016.09.009 27823753
128. Brinton RD Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action Ann N Y Acad Sci 2005 1052 57 74 10.1196/annals.1347.005 16024751
129. Dye Richelin V. Miller Karen J. Singer Elyse J. Levine Andrew J. Hormone Replacement Therapy and Risk for Neurodegenerative Diseases International Journal of Alzheimer's Disease 2012 2012 1 18 10.1155/2012/258454
130. Imtiaz B Taipale H Tanskanen A Tiihonen M Kivipelto M Heikkinen AM Risk of Alzheimer's disease among users of postmenopausal hormone therapy: a nationwide case-control study Maturitas. 2017 98 7 13 10.1016/j.maturitas.2017.01.002 28274328
131. Shumaker SA Legault C Rapp SR Thal L Wallace RB Ockene JK Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial Jama. 2003 289 20 2651 2662 10.1001/jama.289.20.2651 12771112
132. Wharton W Baker LD Gleason CE Dowling M Barnet JH Johnson S Short-term hormone therapy with transdermal estradiol improves cognition for postmenopausal women with Alzheimer's disease: results of a randomized controlled trial J Alzheimers Dis 2011 26 3 495 505 10.3233/JAD-2011-110341 21694454
134. Espeland MA Rapp SR Manson JE Goveas JS Shumaker SA Hayden KM Long-term effects on cognitive trajectories of postmenopausal hormone therapy in two age groups J Gerontol A Biol Sci Med Sci 2017 72 6 838 845 27506836
135. Fox M Berzuini C Knapp LA Cumulative estrogen exposure, number of menstrual cycles, and Alzheimer's risk in a cohort of British women Psychoneuroendocrinology. 2013 38 12 2973 2982 10.1016/j.psyneuen.2013.08.005 24064221
136. Marjoribanks J Farquhar C Roberts H Lethaby A Lee J Long-term hormone therapy for perimenopausal and postmenopausal women Cochrane Database Syst Rev 2017 1 Cd004143 28093732
137. Mattei TA Is it all about contact? Neurodegeneration as a “protein freeze tag game” inside the central nervous system Front Neurol 2013 4 75 10.3389/fneur.2013.00075 23785353
139. Johnson SC Koscik RL Jonaitis EM Clark LR Mueller KD Berman SE The Wisconsin registry for Alzheimer's prevention: a review of findings and current directions Alzheimers Dement (Amst) 2018 10 130 142 29322089
※ AI-Helper는 부적절한 답변을 할 수 있습니다.